




# GLOBAL MARKET OF ANTIDEPRESSANTS

# INTRODUCTION


- Antidepressants are medications used to treat depression and other related mental health conditions. They work by affecting the balance of chemicals in the brain called neurotransmitters, which are involved in mood regulation.
- There are several classes of antidepressant medications, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Each class of antidepressants works in slightly different ways and may have different side effects.
- SSRIs are the most prescribed type of antidepressant and include medications such as fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro). They primarily increase the levels of serotonin, a neurotransmitter associated with mood regulation, in the brain.
- SNRIs, such as venlafaxine (Effexor) and duloxetine (Cymbalta), work by increasing levels of both serotonin and norepinephrine, another neurotransmitter involved in mood regulation.
- TCAs and MAOIs are older classes of antidepressants that are generally used when other treatments have not been effective or when specific symptoms or conditions require their use.



# Antidepressants

## Market Assessments and Forecasting

# Global Antidepressants Market Segmentation




# MARKET ASSESSMENT

With a compound annual growth rate (CAGR) of 5.9%, the global antidepressant market increased from \$16.44 billion in 2022 to \$17.41 billion in 2023. At least temporarily, the Russia-Ukraine conflict hampered the possibilities of a COVID-19 pandemic-related global economic rebound. Economic sanctions on several nations, an increase in commodity prices, and disruptions in the supply chain due to the conflict between these two nations have caused inflation in the prices of products and services and had an impact on numerous markets worldwide.



Sales, USD Billion




Value-wise market – USD 17.41 billion

# MARKET FORECAST




- At a CAGR of 10.0%, the antidepressant market is anticipated to increase from \$25.52 billion in 2027.
- During the COVID-19 outbreak, the market for antidepressants has also experienced a boom. Anxiety levels are rising globally as a result of the rising instances and fatalities, which has an impact on mental health. People who already have mental health issues are under more stress as a result of the COVID-19 outbreak. Antidepressant drug demand has been sparked by this.

## SALES, USD BILION




# MARKET DRIVER



The major driver of the antidepressant drug industry's expansion globally is the increase in mental health disorders, as many consumers depend on these drugs to treat depression, anxiety disorders, and other mental illnesses.

Drugs that treat depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder are all examples of disorders that are treated with antidepressants. The prevalence of depression ranges from 2% to 6% worldwide, and older people are more likely than younger people to have depression. WHO estimates that 264 million people worldwide, of all ages, suffered from depression in 2020. As a result, it is anticipated that the market for antidepressants will expand due to the increased incidence of mental health conditions.


# Market Barrier



One major barrier impeding the expansion of the antidepressant business is the negative effects of antidepressant medications. Examples include the antidepressants Celexa (citalopram) and Lexapro (escitalopram), both of which are used to treat depression, and Lexapro, which also aids in the treatment of anxiety. Other adverse effects that Lexapro and Celexa might cause include sleepiness, dry mouth, perspiration, nausea, and sleeplessness. Even more serious side effects, such as excessive bleeding, convulsions, and eye problems, are possible with both Celexa and Lexapro. Therefore, it is anticipated that the adverse effects of antidepressant medications will restrain the antidepressant market's expansion.



# MARKET TREND



A significant trend in the antidepressant market is the treatment of resistant depression. The new medication, ketamine, induces anesthesia during surgery, promotes glutamate synthesis, and encourages the formation of new neuronal connections in the brain. It helps people generate more positive attitudes and behaviors by enhancing the brain's capacity for adaptability and the formation of new neural connections. For instance, ketamine, which is one-half of the ketamine component, was recently approved by the Food and Treatment Administration (FDA) as a novel ketamine depression treatment. Patients must also be taking another antidepressant at the same time as the medication, which must be administered as a nasal spray. Additionally, only individuals who have tried two antidepressants unsuccessfully can be prescribed the medication.

# CONCLUSION



- A drug that helps treat depressive symptoms is referred to as an antidepressant. They can also help with the treatment of social anxiety disorder, as well as other anxiety disorders. Antidepressants may have unpleasant side effects. In the beginning, signs and symptoms including nausea, weight gain, or sleep problems may be common.
- In 2022, the antidepressants market's largest region was North America. During the anticipated period, the Middle East is anticipated to experience the highest rate of growth in the worldwide antidepressant market.
- Selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and monoamine oxidase inhibitors (MAOI) are the four primary product classes of antidepressants. Serotonin reuptake inhibitors (SSRIs) are a class of drugs that are frequently prescribed to treat depression and a few other mental diseases. For the treatment of the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder, a variety of medications are used, including monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants.

# CONCLUSION



- Rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder, and other mental diseases.
- Increasing cases of mental health disorders are expected to drive the growth of the antidepressant market.
- The side effects of antidepressant drugs are expected to limit the growth of the antidepressant market.
- A significant trend in the antidepressant market is the treatment of resistant depression. The new medication, ketamine, induces anesthesia during surgery, promotes glutamate synthesis, and encourages the formation of new neuronal connections in the brain.
- The leading players identified are Allergan PLC., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC., H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun Pharmaceuticals Pvt Ltd., Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd., Forest laboratories and Akeda Pharmaceutical.

# CONCLUSION



- Sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline make up the antidepressant market. Factory gate values, or the price of items sold by producers or creators to other businesses (such as downstream producers, wholesalers, distributors, and retailers), as well as to final consumers directly, are the standards in this market. The creators of the items that provide associated services are included in the value of the commodities in this market.
- The market value is defined as the income that businesses receive in terms of the currency (in USD unless otherwise indicated) from the sale of goods and/or services within the specified market and area through sales, grants, or contributions.
- Regardless of where they are produced, the revenues for a specific geographical area consumption values, which are revenues made by businesses in the stated area inside the market. Revenues from resales along the supply chain, whether they occur later or as a component of other items are excluded.